Find A Doctor

Uniting Eva Pharma and the medical community.

Eva Pharma brings you Egypt’s first online medical index. This index helps you find the right physician for your medical needs, close to your home, providing you with their contact information and address.

Browse By Type

Location


Speciality

Gender

Search By Name


 

The Supreme Committee for Viruses Recognizes EVA Pharma as a Partner in the Eradication of Virus C in Egypt


Egyptian Study Proves Virus C Medicines Effective Against COVID-19

  • The committee for viruses: “EVA Pharma is our partner at the eradication of virus C… and soon will release treatment for virus B”
  • Esmat: “we have a complete system to treat all virus C patients including relapsed cases and children… The new treatment will be beneficial for patients with concurrent renal dysfunction”
  • Esmat: “Nucleobuvir® and Daclaviridin® accelerate the healing process, reduce the health effects and death rate of COVID-19 “
  • Armanious: “we are keen on providing the latest antiviral treatments to Egypt and the world”

July 29, 2020, In light of World Hepatitis Day, celebrated on July 28th, the National Committee for Control of Viral Hepatitis, in collaboration with EVA Pharma, held a scientific conference on the updates of the fight against viral hepatitis.

During the conference, Dr. Gamal Esmat, vice chairman of the National Committee for Control of Viral Hepatitis of the Ministry of Health and Population, and the World Health Organization advisor, shared WHO’s goal to eliminate viral hepatitis globally by the year 2030. The goal which Egypt has already accomplished in virus C, Esmat highlighted “we are the first country to reach this rate of virus C elimination”.

Esmat commended EVA Pharma’s collaboration with Gilead Sciences to provide Egypt with a complete virus C treatment system, including high-quality medicines for relapsed cases and children.

As for the fight against hepatitis B, Esmat praised the novel medicine which EVA Pharma is planning its release soon. The medicine, as Esmat clarified, will benefit hepatitis B patients with renal dysfunction, unlike current treatments that have more load and kidney-related side effects.

On the margin of the conference, Esmat shared the positive results of an Egyptian study on the effect of HCV treatments on the novel coronavirus. The study, which was held at the faculty of sciences, Cairo University, has theoretically proved that HCV treatments as Nucleobuvir®, with active ingredient sofosbuvir, and Daclaviridin®, with active ingredient daclatasvir, accelerate the healing process, reduce the health effects and death rate of COVID-19.

Esmat added, after the conclusion of the study at Cairo’s faculty of sciences, 4 countries are now investigating the effects of HCV treatments on COVID-19. The countries are Egypt, Brazil, South Africa, and Iran.

Meanwhile, Dr. Riad Armanious, chief executive officer of EVA Pharma, said his company is keen on providing novel treatments to Egyptians; which allows the company to actively support the country’s quest to eliminate hepatitis C, in addition to its efforts to supply other antiviral treatments for hepatitis B, HIV, influenza, or coronavirus.

EVA Pharma owns the biggest pharmaceutical research center in the Middle East and Africa, Mounir Armanious Research Center (MARC), Armanious added. The company focuses on supporting scientific research and Egyptian researchers as well as the local manufacturing of active pharmaceutical ingredients and novel medicines.

While Dr. Amgad Talaat, general manager at EVA Pharma, said the company was a partner at the success of the president’s health campaign to eliminate hepatitis C. Talaat added, EVA Pharma, in collaboration with the Supreme Committee for Control of Viral Hepatitis and the Egyptian Society of Internal Medicine, will train more than a thousand hepatologist and infectious diseases specialist on the most recent treatments for hepatitis patients, as well as ultrasound diagnostic measures.

 

Download as PDF


EVA Pharma Explores the Manufacturing of COVID-19 Vaccines with European and American Companies


  • Armanious: “We are willing to cooperate with all parties that will provide the Egyptian patient a head start. We are establishing a whole city to manufacture vaccines in Egypt.”
  • EVA Pharma’s CEO: “We will produce the human and veterinary vaccines. The city will be completed within 3 to 5 years & our first product, a veterinary vaccine will be released within 3 months.”
  • Ayman Al-Deib: “200 million birds will be vaccinated against influenza and Newcastle disease before winter 2021”

 

Cairo, July 28, 2020 – EVA Pharma announced its efforts at concluding cooperation agreements to manufacture a vaccine for the novel coronavirus in Egypt.

In the meantime, Dr. Riad Armanious, EVA Pharma’s CEO, said that they started communicating with various international companies, both European and American, working on the development of coronavirus vaccine and that EVA Pharma is willing and prepared to cooperate with all parties that will provide the Egyptian patient with a head start at attaining the COVID-19 vaccine.

In his press statement, earlier today, Armanious added that the manufacturing of the vaccine in Egypt will ensure its affordability to the Egyptian patient & the availability in any quantities needed by the national market in addition to its high quality.

Armanious emphasized the company’s keenness to cover the needs of the Egyptian patient while facing the coronavirus, including antiviral treatments, immunity-boosting agents, all supportive treatments in addition to the vaccine.

He clarified that his company started implementing a massive national project to build the first medical city specialized in manufacturing human and veterinary vaccines in Egypt, Africa and the middle east.

This step comes in alignment with the company’s mission to secure the needs of the Egyptian citizens as well as citizens in all the continents where the company operates. The first phase of the project will include veterinary vaccines along with the quest to produce COVID-19 vaccines after proven effective globally.

The company consulted two of the biggest international expert houses to develop construction designs of the human and veterinary vaccine plant according to the global standards, before the emerging of the novel coronavirus. The plant will contribute towards the self-sufficiency of the vaccines and provide Egypt with hard currency with the export.

Armanious added, “owning a medical city that is specialized in producing vaccines will enable Egypt to produce, with high speed and quality, vaccines against any future microbial threat; as it will also open doors to collaboration with the leading global institutes in the vaccination field including vaccines against different viruses”.

Armanious pointed that EVA Pharma’s first vaccine product will be released before the end of 2020, as it will be used to vaccinate a huge amount of birds and poultry against winter-related viruses as “influenza” and “Newcastle disease”. The project, as highlighted by Armanious, will protect almost 10% of Egypt’s poultry fortune from winter-related respiratory viruses, a number that is estimated from 100 to 200 million different birds.

The vaccine city will be complete within 3 to 5 years, the time which EVA Pharma is investing in preparing the manufacturing process of different vaccines.

From his part, Dr. Ayman Al-Deib, assistant professor in viruses at the veterinary medical college in Cairo University and the technical consultant of EVA Pharma on its veterinary vaccinations portfolio, said the company has already successfully registered two veterinary vaccines which will be its first vaccine products.

Al-Deib added, the two vaccines will be available at the national markets within 2 to 3 months at the most estimate, with the help and cooperation of the Serums and Vaccines Research Institute of Ministry of Agriculture and Land Reclamation.

Clarifying that such vaccines are usually imported, Al-Deib said that the Egyptian vaccines will reduce the influenza and Newcastle disease death toll of poultry, which resolves a big problem at the poultry industry, when a safe, high quality and affordable vaccine is available.

download as pdf


The Telegraph announced that “Sofosbuvir” and “Daclatasvir” Produced by EVA Pharma are reducing Coronavirus Death Rate


  • EVA Pharma: It’s our duty to provide all needed quantities in Egypt

Cairo, July 11, 2020 A number of countries are currently investigating the effects of two hepatitis C treatments on reducing the death rate of coronavirus. Three trials involved patients in Iran, along with other similar trials simultaneously conducted in other countries.

The trials included “Sofosbuvir” and “Daclatasvir”; both drugs are produced by EVA Pharma, one of the major international pharmaceutical companies headquartering in Cairo while operating in more than 40 countries. The two drugs were used during the country’s campaign to eliminate hepatitis C from Egypt.

According to The Telegraph, “Three groups of patients were given the two drugs, with affordable cost of the treatment compared to other tested COVID-19 treatments” the results of such trials were described as “promising”.

The mechanism of action for the mentioned treatments, by binding to one of the proteins of the virus, interfering with its ability to replicate. The results of the trials are expected to be concluded and revealed in October.

In his comment on the current studies, Dr. Riad Armanious, CEO of EVA Pharma, assured the company’s commitment to producing both drugs at enough quantities to cover the Egyptian needs especially with EVA Pharma having vast manufacturing capabilities that allow export.

Armanious also highlighted that now EVA Pharma offers Egypt and all countries in the region, all the treatment options available to combat coronavirus. Starting from the antivirals “Remdesivir – EVA Pharma”, up to “Sofosbuvir” and “Daclatasvir” and all other drugs included in COVID-19 treatment will be made available in high-value and affordable cost to the Egyptian patient.

While pointing that his company produces a group of vitamins and immunity boosters as vitamin C and zinc, vitamin B complex, along with other needed drugs that allow Egypt’s “White Army” to treat COVID-19 patients in Egyptian hospitals, and other countries in the region and globally.

Armanious revealed that EVA Pharma has already released Remdesivir to nearly 30 hospitals around Egypt, while now is getting ready to export abroad in the upcoming few days.

Wrapping his statement, Armanious assured again in his company’s quest to provide all and any treatment production amounts serving the best interest of the Egyptian patient, and openness to abroad export.

 

Download as PDF


EVA Pharma launches the first Egyptian medication for Chronic Obstructive Pulmonary Disease


  • “Inhalex” the first Egyptian medication for COPD patients that provides affordable treatment, regular availability in the Egyptian market, and a 24-hour lasting effect.
  • Egyptian medicine will reduce the cost of treatment to half.

 

Cairo, July 20, 2020 – EVA Pharma today announced the launch of the Egyptian drug Inhalex® (tiotropium) a long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) which will reduce the cost of treatment for the patient to half.

“Throughout 5 years of work and consulting German expertise, we have been able to manufacture this high-quality product,” said one of the researchers at EVA Pharma on Inhalex.

“Inhalex reduces the cost of treatment to half.” said Dr.Ashraf Hatem, member of the High Committee for Respiratory Viruses at the Ministry of Higher Education & Scientific Research, the former Minister of Health and Population “As smokers, secondhand smokers and who are exposed to severe pollution are the most affected, this treatment helps COPD patients breathe normally throughout the day.”

In his press statement earlier today, Dr.Hatem said that the disease prevalence is 5-10% of the population, estimating that 10 million Egyptians suffer from COPD & it’s prevalent not only in Egypt but also globally.

The Egyptian drug “Inhalex”, a generic product for a similar previously imported drug, will reduce the patient’s treatment cost to half, as it’s a medicine that has to be administered daily for a lifetime.

Hatem added, “COPD patients had no other option but to buy the imported drug, to help them breathe normally to be able to do their daily activities. The Egyptian “Inhalex” will provide an affordable treatment, regular availability in the Egyptian market and a 24-hour lasting effect of the treatment”

“COPD patient needs this treatment for life; it is important for the patient to have a generic drug similar to the imported treatment in the Egyptian market with an affordable price since the imported drug is double the cost of the Egyptian Inhalex” stated Hatem.

He also emphasized the importance of asthma and COPD patients’ adherence to their daily treatment to avoid exacerbation of viral infections including the COVID-19 and to have fewer effects in case the patients have a viral exacerbation.

Hatem valued the efforts made by EVA Pharma to produce this drug in Egypt, including importing the pharmaceutical active ingredients and the apparatus used to inhale the active ingredient, along with high manufacturing quality. Illustrating that “a good generic product attracts the patient due to its effectiveness and affordability.”

 

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo while operating in more than 40 countries, is currently launching “Inhalex” in the national market. The new drug “Inhalex” has the same quality as the imported drug with a 50% price reduction. And EVA Pharma is able to provide any required quantity to the national market, along with international export” said Dr. Mina Henien, a senior R&D manager at EVA Pharma’s Mounir Armanious Research Center (MARC).

 

He added that EVA Pharma owns a set of laboratories that ensures the product’s quality, as Inhalex was tested on an artificial lung to ensure the product’s high effectiveness as part of the testing process applied at the top international companies of the pharmaceutical field. Henien explained that EVA Pharma has been examining the manufacturing of this drug 5 years ago, while delegates from the company traveled to Kiel University in Germany to share their experience in this field for the highest international manufacturing quality. The new drug delivers the active constituent directly to the lung via an inhaler that is included in each package of Inhalex, thus ensuring optimal treatment effectiveness for the patient.

 

About Inhalex®

Its active ingredient is (tiotropium), a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease and asthma. Which provides affordable treatment, regular availability in the Egyptian market, and a 24-hour lasting effect.

About COPD

The major cause of COPD prevalence in Egypt and the world is cigarette or hookah smoking. Its symptoms include cough, shortness of breath, and inability to breathe normally.

COPD is more common in men, due to smoking, but there is prevalence among women in Upper Egypt who use traditional ovens and have been exposed to smoke for long periods, or who are living in areas with severely polluted air for a long time.

 

About EVA Pharma

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo, Egypt while operating in more than 40 countries and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 41 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, Eva Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards.

Download as PDF


EVA Pharma Granted License to Manufacture and Distribute “Remdesivir” in 127 countries


Egypt, June 14, 2020

Having reached a landmark agreement with Gilead Sciences Inc., EVA Pharma is proud to announce that it is now a licensed manufacturer for the antiviral treatment Remdesivir in 127 countries. This game-changing development establishes EVA Pharma’s position as a global leader in the battle against COVID-19. Accordingly, it will work at ‘full capacity’ while leveraging its far-reaching network to meet the onerous challenge of alacritous providing Remdesivir to all COVID-19 patients in 127 countries.

“This voluntary license agreement comes at a critical time as the virus has started to spread in developing countries whose health-care systems are already severely strained. It is our duty to rise to the occasion and support our fellow man as humanity collectively strives to put an end to this pandemic. EVA Pharma is therefore working tirelessly and assiduously to ensure the availability of life-saving drugs to COVID-19 patients”
said EVA Pharma CEO, Riad Armanious.

EVA group and Gilead have a history of highly successful partnerships, having fruitfully collaborated in the past to provide accessible, affordable, and high-quality treatments of otherwise lethal infectious diseases such as HIV and hepatitis C to millions of patients in Africa.

“We are thrilled to have been chosen to work side-by-side with Gilead
sciences once more. We strongly believe that our partnership with
Gilead will help us realize our vision of empowering the fight for health
and well-being as a human right”
said Armanious

Remdesivir is an investigational new drug developed by Gilead Sciences. The treatment has recently been granted an emergency use authorization (EUA) to treat hospitalized COVID-19 patients in the U.S and the UK.

Besides, it is recommended for compassionate use in Europe and recently received regulatory approval in Japan. Two global clinical trials conducted to date have demonstrated positive results, reducing the recovery time for patients with COVID-19, although the full efficacy and safety of the treatment are still under investigation. The voluntary license agreement provides EVA Pharma with Gilead’s technology, manufacturing process descriptions, specifications, and methods to boost the production timeline of Remdesivir.

About Gilead

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at gilead.com

About EVA Pharma

EVA Pharma is a leading international pharmaceutical company based in Cairo, Egypt, and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 42 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, EVA Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards. To learn more about EVA Pharma, please visit evapharma.com

Download as pdf


Loading